Literature DB >> 29942223

Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease.

Brian Feagan1.   

Abstract

Entities:  

Year:  2018        PMID： 29942223      PMCID： PMC6009184     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

1.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

Authors:  Bruce E Sands; Brian G Feagan; Paul Rutgeerts; Jean-Frédéric Colombel; William J Sandborn; Richmond Sy; Geert D'Haens; Shomron Ben-Horin; Jing Xu; Maria Rosario; Irving Fox; Asit Parikh; Catherine Milch; Stephen Hanauer
Journal:  Gastroenterology       Date:  2014-05-21       Impact factor: 22.682

2.  Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.

Authors:  Brian G Feagan; David T Rubin; Silvio Danese; Severine Vermeire; Brihad Abhyankar; Serap Sankoh; Alexandra James; Michael Smyth
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 11.382

Review 3.  Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.

Authors:  Mahmoud H Mosli; John K MacDonald; Stephen J Bickston; Brian W Behm; David J Tsoulis; Jianfeng Cheng; Reena Khanna; Brian G Feagan
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

Review 4.  The safety of vedolizumab for the treatment of ulcerative colitis.

Authors:  Gregor Novak; Pieter Hindryckx; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Expert Opin Drug Saf       Date:  2017-03-05       Impact factor: 4.250

5.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

6.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

7.  The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Authors:  Jean-Frédéric Colombel; Bruce E Sands; Paul Rutgeerts; William Sandborn; Silvio Danese; Geert D'Haens; Remo Panaccione; Edward V Loftus; Serap Sankoh; Irving Fox; Asit Parikh; Catherine Milch; Brihad Abhyankar; Brian G Feagan
Journal:  Gut       Date:  2016-02-18       Impact factor: 23.059
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.